Humacyte, Inc. (HUMA) on Thursday said it plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the fourth quarter for its coronary tissue engineered vessel (CTEV) in coronary artery bypass grafting (CABG).
The company also announced the publication of new data in the Journal of the American College of Cardiology from a study evaluating CTEV as a coronary artery bypass graft conduit in a non-human primate model.
Humacyte said all implanted CTEVs remained patent throughout the six-month study and recellularized with host cells, suggesting that CTEV could serve as a durable alternative conduit for CABG.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.